United States Biotechnology & Medical Research

Axovant Gene Therapies Ltd (AXGT)

Track

Ticker: AXGT Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
No insider activity signals detected

Insider trades have not triggered unusual activity signals for this company.

Top insiders
Trades
Buy 23 Mar 2021
Value US$3,746,057.74 | Price 318.60 | Shares 10,237 (+38.6%)
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2021-03-24 2021-03-23 B Purchase
Cheruvu Pavan

Chief Executive Officer

Executive Director
10,237 +38.6%
318.60
US$3,746,058 		10,237 +38.6% 318.60 US$3,746,058
2020-11-25 2020-11-24 B Purchase
3.4
Pande Atul
Non-Executive Director
58,596 -13.2%
138.78
US$3,660,196 		58,596 -13.2% 138.78 US$3,660,196
2020-07-10 2020-07-08 B Purchase
Cheruvu Pavan

Principal Executive Officer

Executive Director
37,969 +45.7%
194.92
US$1,331,093 		37,969 +45.7% 194.92 US$1,331,093
2020-07-10 2020-07-08 B Purchase
3.4
Pande Atul
Non-Executive Director
10,000 +74.8%
2.73
US$27,290 		10,000 +74.8% 2.73 US$27,290
2020-03-18 2020-03-16 B Purchase
3.4
Pande Atul
Non-Executive Director
10,000 +296.7%
1.78
US$17,844 		10,000 +296.7% 1.78 US$17,844
2020-02-27 2020-02-24 B Purchase
1.9
Roivant Sciences Ltd.
Large shareholder
5,333,333 +40.3%
3.75
US$19,999,999 		5,333,333 +40.3% 3.75 US$19,999,999
2019-06-17 2019-06-14 B Purchase
3.4
Pande Atul
3,370 +inf%
5.22
US$17,595 		3,370 +inf% 5.22 US$17,595
2019-06-17 2019-06-14 B Purchase
Cheruvu Pavan

Chief Executive Officer

Executive Director
7,500 +inf%
5.21
US$39,075 		7,500 +inf% 5.21 US$39,075
2019-03-19 2019-03-18 B Purchase
1.9
Roivant Sciences Ltd.
Large shareholder
6,666,667 +6.7%
1.50
US$10,000,000 		6,666,667 +6.7% 1.50 US$10,000,000
2019-03-19 2019-03-18 B Purchase
1.5
Machado Patrick
Large shareholder
6,666,667 +6.7%
1.50
US$10,000,000 		6,666,667 +6.7% 1.50 US$10,000,000
2019-03-19 2019-03-18 B Purchase
Dexxon Holdings Ltd.
Large shareholder
6,666,667 +6.7%
1.50
US$10,000,000 		6,666,667 +6.7% 1.50 US$10,000,000
2019-03-19 2019-03-18 B Purchase
QVT Associates GP LLC
Large shareholder
6,666,667 +6.7%
1.50
US$10,000,000 		6,666,667 +6.7% 1.50 US$10,000,000
2019-03-19 2019-03-18 B Purchase
3.2
SVF Investments (UK) Ltd
Large shareholder
6,666,667 +6.7%
1.50
US$10,000,000 		6,666,667 +6.7% 1.50 US$10,000,000
2019-03-19 2019-03-18 B Purchase
2.5
Lo Andrew
Large shareholder
6,666,667 +6.7%
1.50
US$10,000,000 		6,666,667 +6.7% 1.50 US$10,000,000
2019-03-19 2019-03-18 B Purchase
3.2
VIKING GLOBAL INVESTORS LP
Large shareholder
6,666,667 +6.7%
1.50
US$10,000,000 		6,666,667 +6.7% 1.50 US$10,000,000
2019-03-19 2019-03-18 B Purchase
2.0
VIKING GLOBAL PERFORMANCE LLC
Large shareholder
6,666,667 +6.7%
1.50
US$10,000,000 		6,666,667 +6.7% 1.50 US$10,000,000
2018-12-20 2018-12-18 B Purchase Roivant Sciences Ltd. Large shareholder
10,000,000 +11.2%
1.00
US$10,000,000 		10,000,000 +11.2% 1.00 US$10,000,000
2018-12-20 2018-12-18 B Purchase SVF Investments (UK) Ltd Large shareholder
10,000,000 +11.2%
1.00
US$10,000,000 		10,000,000 +11.2% 1.00 US$10,000,000
2018-12-20 2018-12-18 B Purchase VIKING GLOBAL PERFORMANCE LLC Large shareholder
10,000,000 +11.2%
1.00
US$10,000,000 		10,000,000 +11.2% 1.00 US$10,000,000
2018-12-20 2018-12-18 B Purchase Dexxon Holdings Ltd. Large shareholder
10,000,000 +11.2%
1.00
US$10,000,000 		10,000,000 +11.2% 1.00 US$10,000,000
2018-12-20 2018-12-18 B Purchase VIKING GLOBAL INVESTORS LP Large shareholder
10,000,000 +11.2%
1.00
US$10,000,000 		10,000,000 +11.2% 1.00 US$10,000,000
2018-12-20 2018-12-18 B Purchase Lo Andrew Large shareholder
10,000,000 +11.2%
1.00
US$10,000,000 		10,000,000 +11.2% 1.00 US$10,000,000
2018-12-20 2018-12-18 B Purchase Machado Patrick Large shareholder
10,000,000 +11.2%
1.00
US$10,000,000 		10,000,000 +11.2% 1.00 US$10,000,000
2018-12-20 2018-12-18 B Purchase QVT Associates GP LLC Large shareholder
10,000,000 +11.2%
1.00
US$10,000,000 		10,000,000 +11.2% 1.00 US$10,000,000
2018-08-13 2018-08-09 B Purchase Bickerstaff George Non-Executive Director
25,000 +100.0%
2.07
US$51,750 		25,000 +100.0% 2.07 US$51,750
2018-06-07 2018-06-05 B Purchase SVF Investments (UK) Ltd Large shareholder
14,285,714 +19.0%
1.75
US$25,000,000 		14,285,714 +19.0% 1.75 US$25,000,000
2018-06-07 2018-06-05 B Purchase Roivant Sciences Ltd. Large shareholder
14,285,714 +19.0%
1.75
US$25,000,000 		14,285,714 +19.0% 1.75 US$25,000,000
2018-06-07 2018-06-05 B Purchase Dexxon Holdings Ltd. Large shareholder
14,285,714 +19.0%
1.75
US$25,000,000 		14,285,714 +19.0% 1.75 US$25,000,000
2018-06-07 2018-06-05 B Purchase Lo Andrew Large shareholder
14,285,714 +19.0%
1.75
US$25,000,000 		14,285,714 +19.0% 1.75 US$25,000,000
2018-06-07 2018-06-05 B Purchase VIKING GLOBAL PERFORMANCE LLC Large shareholder
14,285,714 +19.0%
1.75
US$25,000,000 		14,285,714 +19.0% 1.75 US$25,000,000
2018-06-07 2018-06-05 B Purchase QVT Associates GP LLC Large shareholder
14,285,714 +19.0%
1.75
US$25,000,000 		14,285,714 +19.0% 1.75 US$25,000,000
2018-06-07 2018-06-05 B Purchase Machado Patrick Large shareholder
14,285,714 +19.0%
1.75
US$25,000,000 		14,285,714 +19.0% 1.75 US$25,000,000
2018-06-07 2018-06-05 B Purchase VIKING GLOBAL INVESTORS LP Large shareholder
14,285,714 +19.0%
1.75
US$25,000,000 		14,285,714 +19.0% 1.75 US$25,000,000
2018-03-01 2018-02-27 B Purchase Bickerstaff George
25,000 +inf%
1.50
US$37,425 		25,000 +inf% 1.50 US$37,425
2017-04-19 2017-04-17 B Purchase Hung David

Principal Executive Officer

Executive Director
539,375 +inf%
18.54
US$10,000,012 		539,375 +inf% 18.54 US$10,000,012
2017-04-19 2017-04-17 B Purchase FALBERG KATHRYN E
53,937 +inf%
18.54
US$999,992 		53,937 +inf% 18.54 US$999,992
2017-04-19 2017-04-17 B Purchase VERNON W ANTHONY
53,937 +inf%
18.54
US$999,992 		53,937 +inf% 18.54 US$999,992
2016-03-14 2016-03-10 B Purchase Altmeyer Mark

Pres&Chief Commercial Officer

Officer
2,300 +inf%
11.14
US$25,622 		2,300 +inf% 11.14 US$25,622
Explore more

More insider trading research around Axovant Gene Therapies Ltd

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America